"Some people will feel that this is still not satisfactory public policy," Hanson (James Hanson, M.D., acting chief of the National Cancer Institutes Clinical and Genetic Epidemiology Research Branch) acknowledged, "but it was the best we could do at this time," given Myriads intellectual property rights to the gene.
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |